How should a 50-year-old male with hypertension (blood pressure 140/90 mmHg on cilnidipine (calcium‑channel blocker)‑telmisartan (angiotensin‑II receptor blocker)), hypercalcemia, hyperuricemia, a history of renal calculi, mild renal impairment (creatinine ~1.6 mg/dL, eGFR ≈50 mL/min) and low‑grade proteinuria be managed by a nephrologist?

Comprehensive Nephrological Management of a 50-Year-Old Male with Hypercalcemia, Hyperuricemia, and CKD

Immediate Priority: Investigate and Treat Hypercalcemia

The hypercalcemia (12.1 mg/dL) is the most urgent abnormality requiring immediate workup, as it may represent primary hyperparathyroidism—a treatable cause of both renal dysfunction and nephrolithiasis in this patient and his daughters. 1

Essential Diagnostic Workup for Hypercalcemia

• Measure intact parathyroid hormone (PTH), 25-hydroxyvitamin D, and ionized calcium to differentiate primary hyperparathyroidism from other causes of hypercalcemia 1
• Order 24-hour urine calcium, phosphate, and creatinine to calculate fractional excretion and assess for familial hypocalciuric hypercalcemia versus primary hyperparathyroidism 1
• Check serum phosphate levels, as hypophosphatemia with hypercalcemia strongly suggests primary hyperparathyroidism 1
• The family history of nephrolithiasis in two daughters at young ages (13 and 17 years) raises suspicion for hereditary hyperparathyroidism or familial hypocalciuric hypercalcemia 1

Blood Pressure Management: Intensify to Target <130/80 mmHg

This patient's blood pressure of 140/90 mmHg exceeds the recommended target of <130/80 mmHg for patients with CKD and proteinuria (UPCR 0.26 g/g). 2, 3

Specific Medication Adjustments

• Add chlorthalidone 12.5-25 mg once daily to the current cilnidipine-telmisartan regimen, as thiazide-type diuretics provide superior cardiovascular outcomes and are recommended as part of triple therapy for CKD 2, 4
• The current combination of telmisartan (ARB) plus cilnidipine (calcium channel blocker) is appropriate, but insufficient to achieve target BP 1, 2
• Monitor serum calcium closely after adding thiazide, as thiazides reduce urinary calcium excretion and may worsen hypercalcemia 1
• Recheck BP, creatinine, and potassium within 2-4 weeks of adding the thiazide diuretic 2, 3

Rationale for Cilnidipine Continuation

• Cilnidipine (N/L-type calcium channel blocker) has demonstrated superior antiproteinuric effects compared to amlodipine in CKD patients, with significant reductions in urinary albumin-to-creatinine ratio 5, 6
• Cilnidipine also reduces uric acid production in patients with elevated urinary uric acid/creatinine ratios (≥0.5), which may benefit this patient with hyperuricemia 5
• The combination of ARB plus cilnidipine reduces inflammation, oxidative stress, and arterial stiffness more effectively than ARB plus thiazide alone 7

Hyperuricemia Management: Initiate Urate-Lowering Therapy

With serum uric acid of 9.2 mg/dL and CKD, this patient should receive urate-lowering therapy even without symptomatic gout, as this level exceeds 9 mg/dL. 1

Specific Treatment Plan

• Start allopurinol 100 mg once daily (reduced dose for CKD stage 3), titrating gradually every 2-4 weeks to target serum uric acid <6 mg/dL 1
• Xanthine oxidase inhibitors (allopurinol or febuxostat) are preferred over uricosuric agents in CKD patients 1
• Do NOT use urate-lowering therapy solely to slow CKD progression, as evidence does not support this indication in asymptomatic hyperuricemia 1
• The primary indication here is the markedly elevated uric acid level (>9 mg/dL), which warrants treatment to prevent first gout episode 1

Lifestyle Modifications for Hyperuricemia

• Advise limiting alcohol, red meat, organ meats, and high-fructose corn syrup intake to reduce uric acid production 1
• These dietary modifications complement pharmacological therapy 1

Proteinuria Management: Optimize RAAS Blockade

The UPCR of 0.26 g/g (approximately 260 mg/g) represents low-grade albuminuria requiring intensified renin-angiotensin system blockade. 1, 8

Medication Optimization

• Uptitrate telmisartan from current dose to 80 mg once daily if not already at this dose, as 80 mg provides maximal antiproteinuric effect 9, 10
• The FDA label for telmisartan indicates that blood pressure response is dose-related over the range of 20-80 mg, with most antihypertensive effect apparent within 2 weeks 9
• Do NOT add an ACE inhibitor to telmisartan, as dual RAAS blockade increases serious adverse events without additional benefit 1, 9

Monitoring Proteinuria Response

• Recheck UPCR in 3 months after medication adjustments to assess antiproteinuric response 2, 3
• Target UPCR reduction to <150 mg/g if achievable with current therapy 1, 8

Cardiovascular Risk Reduction: Add Statin Therapy

This 50-year-old male with CKD stage 3 (eGFR approximately 50 mL/min based on creatinine 1.57) and multiple cardiovascular risk factors requires statin therapy. 1, 2

Specific Statin Recommendation

• Initiate atorvastatin 20-40 mg once daily or rosuvastatin 10-20 mg once daily to reduce cardiovascular events 1, 2
• The 2024 KDIGO guidelines recommend statin or statin/ezetimibe combination for adults ≥50 years with eGFR <60 mL/min/1.73 m² 1
• Target LDL cholesterol <1.70 mmol/L (<70 mg/dL) given high cardiovascular risk from CKD, hypertension, and likely metabolic syndrome (triglycerides 183 mg/dL) 2

Aspirin Consideration

• Continue aspirin 75 mg daily for primary prevention, as this patient has multiple cardiovascular risk factors including CKD, hypertension, and dyslipidemia 1, 2
• Low-dose aspirin is recommended for cardiovascular risk reduction in high-risk patients 1

Renal Stone Disease: Metabolic Evaluation

The history of recurrent nephrolithiasis in the patient and two daughters necessitates comprehensive metabolic stone evaluation. 1

Essential Stone Workup

• Order 24-hour urine collection for volume, calcium, oxalate, citrate, uric acid, sodium, and creatinine to identify metabolic abnormalities 1
• Obtain stone analysis if any stones are available from previous episodes 1
• The combination of hypercalcemia, hyperuricemia, and family history suggests possible primary hyperparathyroidism as the underlying cause 1
• If primary hyperparathyroidism is confirmed, parathyroidectomy may be curative for both hypercalcemia and recurrent nephrolithiasis 1

Dietary and Lifestyle Modifications

Intensive lifestyle interventions provide additive blood pressure reductions of 10-20 mmHg and help manage multiple metabolic abnormalities. 2

Specific Dietary Recommendations

• Restrict sodium intake to <2 g/day (5 g salt/day) to improve blood pressure control and reduce proteinuria 2, 4
• Limit dietary protein to 0.8 g/kg/day to reduce proteinuria and slow CKD progression 1
• Increase fluid intake to maintain urine output >2 L/day to prevent stone recurrence 1
• Adopt a Mediterranean-style diet to reduce cardiovascular risk 1
• Limit potassium-rich processed foods given CKD stage 3 and use of RAAS inhibitor 1

Weight and Exercise Goals

• Target BMI reduction through caloric restriction if overweight (current weight 75.75 kg; BMI calculation needed) 2
• Recommend 150 minutes/week of moderate aerobic exercise to improve blood pressure and cardiovascular health 2

Monitoring Schedule and Follow-Up

Short-Term Follow-Up (2-4 Weeks)

• Recheck basic metabolic panel (creatinine, potassium, sodium, calcium) after adding thiazide diuretic 2, 3
• Measure blood pressure to assess response to intensified therapy 2, 3
• Review PTH and vitamin D results to guide hypercalcemia management 1

Medium-Term Follow-Up (3 Months)

• Assess BP control, targeting <130/80 mmHg 2, 3, 4
• Recheck UPCR to evaluate antiproteinuric response 2, 3
• Measure serum uric acid to assess response to allopurinol and titrate dose 1
• Check lipid panel to evaluate statin efficacy and adjust dose if needed 1, 2
• Monitor eGFR trend to assess CKD progression 1, 11

Long-Term Monitoring (Every 6-12 Months)

• Annual comprehensive metabolic panel, lipid panel, and UPCR 1, 11
• Annual assessment of cardiovascular risk factors 1, 2
• Repeat 24-hour urine stone risk profile if stone disease recurs 1

Critical Pitfalls to Avoid

• Do NOT delay hypercalcemia workup, as untreated primary hyperparathyroidism accelerates CKD progression and increases cardiovascular risk 1
• Do NOT combine ACE inhibitor with ARB, as dual RAAS blockade increases hyperkalemia and acute kidney injury without additional benefit 1, 9
• Do NOT use loop diuretics instead of thiazides at this eGFR level (approximately 50 mL/min), as thiazides remain effective and provide superior cardiovascular outcomes 2, 4
• Do NOT discontinue telmisartan when adding thiazide, as both provide complementary renal and cardiovascular protection through different mechanisms 2, 7
• Do NOT start allopurinol at full dose (300 mg) in CKD, as this increases risk of severe hypersensitivity reactions; start at 100 mg and titrate slowly 1
• Do NOT ignore the family history of nephrolithiasis, as this strongly suggests hereditary metabolic disorder requiring genetic counseling and family screening 1
• Do NOT target BP <120/70 mmHg, as excessive diastolic lowering below 70 mmHg increases cardiovascular risk, particularly coronary events 3, 4

Summary of Medication Regimen

Current Medications to Continue

• Telmisartan 40-80 mg once daily (uptitrate to 80 mg if not already) 9, 10
• Cilnidipine (current dose) once daily 5, 6, 7
• Aspirin 75 mg once daily 1, 2

Medications to Add

• Chlorthalidone 12.5-25 mg once daily 2, 4
• Allopurinol 100 mg once daily (titrate to target uric acid <6 mg/dL) 1
• Atorvastatin 20-40 mg once daily OR rosuvastatin 10-20 mg once daily 1, 2

Pending Hypercalcemia Workup Results

• Management will depend on PTH, vitamin D, and 24-hour urine calcium results 1
• If primary hyperparathyroidism confirmed, refer to endocrine surgery for parathyroidectomy evaluation 1